AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29911503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 26775599 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention focusing on medication compliance, smoking cessation, exercise, inhaler use, and follow-up.
Number of subjects: 260
Study 26775599 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) without pharmacist intervention.
Number of subjects: 260
Study 24314853 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human EPO (rhEPO)
Number of subjects: 20
Study 24314853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhEPO)
Number of subjects: 20
Study 22641932 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct contact person-to-person prayer intervention (six weekly 1-hour sessions)
Number of subjects: 44
Study 20394720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human interferon alpha-2b nasal spray
Number of subjects: 0
Study 20394720 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18550981 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote stimulation (RS) group performed a 10-minute surface electrical stimulation program on the rectus femoris of the non-dominant leg (frequency 100 Hz, impulse 300 micros, 10 seconds on/10 seconds off).
Number of subjects: 36
Study 18550981 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL) relaxed for 10 minutes without performing any training.
Number of subjects: 36
Study 15855073 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program including A Pregnant Woman's Guide to Stop Smoking, a companion video, clinic reinforcement, and patient-centered counseling.
Number of subjects: 265
Study 15855073 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups with nurses and social workers providing the intervention.
Number of subjects: 265
Study 15855073 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual interviews with women who received the intervention.
Number of subjects: 265
Study 11719835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg single infusion)
Number of subjects: 39
Study 11719835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 39
Study 9386675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 3 days of age (n = 25)
Number of subjects: 50
Study 9386675 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 1 month of age (n = 25)
Number of subjects: 50
Study 7898093 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction and physical exercise
Number of subjects: 0
Study 7898093 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 7898093 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 0
Study 7898093 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers and centrally acting drugs
Number of subjects: 0
Study 7898093 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 3298559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone combined with vincristine and prednisolone (VMP)
Number of subjects: 115
Study 3298559 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin combined with vincristine and prednisolone (VAP)
Number of subjects: 115
Study 2754147 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal avoidance of cow's milk, egg, and peanut during the third trimester of pregnancy and lactation; infant use of casein hydrolysate (Nutramigen) for supplementation or weaning, avoidance of solid foods for 6 months; cow's milk, corn, soy, citrus, and wheat for 12 months; egg, peanut, and fish for 24 months
Number of subjects: 288
Study 2754147 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal avoidance of allergenic foods and infant dietary restrictions
Number of subjects: 288
Study 2754147 — intervention group
Group type: COMPARATOR
Intervention: Control group with unrestricted diets and following American Academy of Pediatrics feeding guidelines
Number of subjects: 288
Study 30874886 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 664
Study 30874886 — intervention group
Group type: COMPARATOR
Intervention: No telemonitoring
Number of subjects: 664
Study 28882136 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory information for children undergoing general anaesthesia
Number of subjects: 0
Study 25416738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP)
Number of subjects: 35
Study 25416738 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 23607998 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing neutral pictures
Number of subjects: 0
Study 23607998 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing pleasant pictures
Number of subjects: 0
Study 23607998 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing unpleasant pictures
Number of subjects: 0
Study 21742094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 5745
Study 21742094 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5745
Study 19783767 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog KwikPen
Number of subjects: 232
Study 19783767 — intervention group
Group type: COMPARATOR
Intervention: Vial and Syringe
Number of subjects: 232
Study 19783767 — intervention group
Group type: COMPARATOR
Intervention: FlexPen
Number of subjects: 232
Study 16757759 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2 (1.50 mg/mL)
Number of subjects: 510
Study 16757759 — intervention group
Group type: COMPARATOR
Intervention: Control (intramedullary nail fixation and routine soft-tissue management)
Number of subjects: 510
Study 15251269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alcohol infusion
Number of subjects: 24
Study 11845484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive home follow-up program
Number of subjects: 62
Study 11845484 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional cardiac rehabilitation)
Number of subjects: 62
Study 9766723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine MRI
Number of subjects: 72
Study 9766723 — intervention group
Group type: COMPARATOR
Intervention: Surgery (including spinal fusion)
Number of subjects: 72
Study 7828202 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group (29 patients) - splint therapy, physical therapy, counseling, NSAID medications
Number of subjects: 49
Study 7828202 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (20 patients)
Number of subjects: 49
Study 3352467 — intervention group
Group type: EXPERIMENTAL
Intervention: A mixture containing a fixed proportion of seven essential amino acids (L‐isoleucine 11.5%, L‐leucine 18.0%, L‐lysine 13.1%, L‐methionine 18.0%, L‐phenylalanine 18.0%, L‐threonine 8.2%, L‐valine 13.1%)
Number of subjects: 0
Study 30762141 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of patient-preferred live music (n=47)
Number of subjects: 143
Study 30762141 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of patient-preferred pre-recorded music (n=47)
Number of subjects: 143
Study 30762141 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=49)
Number of subjects: 143
Study 28777195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (Abbott ARCHITECT) measured within 24 hours of intubation
Number of subjects: 1057
Study 28777195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for Sequential Organ Failure Assessment score
Number of subjects: 1057
Study 25873254 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program for secondary falls prevention
Number of subjects: 344
Study 25873254 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual behavior prior to study enrolment)
Number of subjects: 344
Study 23406861 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection mechanical ventilation (group P)
Number of subjects: 60
Study 23406861 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (group C)
Number of subjects: 60
Study 22211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced mental health intervention (family-based cognitive-behavioral therapy session + care linkage telephone contacts)
Number of subjects: 181
Study 22211209 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced mental health intervention
Number of subjects: 181
Study 22211209 — intervention group
Group type: COMPARATOR
Intervention: Usual emergency department care enhanced by provider education
Number of subjects: 181
Study 19147485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion with anti-arrhythmic drugs for 4 weeks
Number of subjects: 102
Study 19147485 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 102
Study 19147485 — intervention group
Group type: COMPARATOR
Intervention: Refractory AF (RAF) group
Number of subjects: 102
Study 19147485 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of AF >5 months
Number of subjects: 102
Study 19147485 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-2 >767.0 ng/mL
Number of subjects: 102
Study 16477828 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular left observation condition
Number of subjects: 0
Study 16477828 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular right observation condition
Number of subjects: 0
Study 16477828 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular observation condition
Number of subjects: 0
Study 16477828 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper and lower boundaries of probability summation
Number of subjects: 0
Study 16477828 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular capacity coefficient
Number of subjects: 0
Study 16477828 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study 15026584 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 19
Study 11403809 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (clarithromycin 500 mg and amoxicillin 1000 mg twice daily) for 10 days
Number of subjects: 70
Study 11403809 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 70
Study 11403809 — intervention group
Group type: COMPARATOR
Intervention: Control group (H pylori-negative)
Number of subjects: 70
Study 9137510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VNB) weekly IV bolus of 30 mg/m (14 patients)
Number of subjects: 30
Study 9137510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VNB) continuous infusion (CI) schedule of 8 mg IV bolus on day 1 followed by 8 mg/m2/die CI day 1 to 4, q 21 days (16 patients)
Number of subjects: 30
Study 12959289 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 12959289 — intervention group
Group type: COMPARATOR
Intervention: Diflunisal
Number of subjects: 0
Study 3501162 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (AP; dipyridamole 400 mg + aspirin 50 mg/day)
Number of subjects: 251
Study 3501162 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation (AC)
Number of subjects: 251
Study 3501162 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (AP)
Number of subjects: 251
Study 28985369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including access to online modules and a face-to-face educational session.
Number of subjects: 528
Study 28985369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 528
Study 26651598 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (10 Hz, 120% motor threshold, 3000 pulses/session, up to 30 sessions)
Number of subjects: 10
Study 25066140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone plus melatonin
Number of subjects: 60
Study 25066140 — intervention group
Group type: COMPARATOR
Intervention: Melatonin only
Number of subjects: 60
Study 22353992 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraspinatus test (IsT)
Number of subjects: 34
Study 22353992 — intervention group
Group type: COMPARATOR
Intervention: Nerve conduction velocity (NCV)
Number of subjects: 34
Study 20461319 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20‐mg capsules twice a day
Number of subjects: 20
Study 20461319 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a day
Number of subjects: 20
Study 17593515 — intervention group
Group type: EXPERIMENTAL
Intervention: steroid/Aza
Number of subjects: 475
Study 17593515 — intervention group
Group type: COMPARATOR
Intervention: steroid/CsA
Number of subjects: 475
Study 16193479 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing plus brief office intervention
Number of subjects: 60
Study 16193479 — intervention group
Group type: COMPARATOR
Intervention: Brief office intervention only
Number of subjects: 60
Study 12173200 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.625 mg i.v.
Number of subjects: 120
Study 12173200 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 120
Study 10441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin treatment (0.4 mg/kg IV bolus, followed by 0.15 mg/kg/h intravenous infusion), n=65
Number of subjects: 112
Study 10441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin treatment in conjunction with thrombolysis (0.2 mg/kg, followed by 0.10 mg/kg/h), n=4
Number of subjects: 112
Study 10441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin prophylaxis (0.10 mg/kg/h), n=43
Number of subjects: 112
Study 10441094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepirudin-treated patients
Number of subjects: 112
Study 10441094 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients
Number of subjects: 112
Study 8588062 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors over an 8-week period
Number of subjects: 0
Study 8588062 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors
Number of subjects: 0
Study 2222943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril (1 to 10 mg delivered at 10 min intervals over 50 to 80 min)
Number of subjects: 24
Study 2222943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril (incremental doses up to 40 mg)
Number of subjects: 24
Study 2222943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril
Number of subjects: 24
Study 2222943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril with hydrochlorothiazide
Number of subjects: 24
Study 215097 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 11
Study 31755967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Ziv-Aflibercept 1.25 mg
Number of subjects: 123
Study 31755967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab
Number of subjects: 123
Study 31755967 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Ziv-Aflibercept 2.5 mg
Number of subjects: 123
Study 27918764 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus onartuzumab (10 mg/kg)
Number of subjects: 562
Study 27918764 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus placebo
Number of subjects: 562
Study 27465372 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fiber from SCF/d
Number of subjects: 14
Study 27465372 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g fiber from SCF/d
Number of subjects: 14
Study 27465372 — intervention group
Group type: COMPARATOR
Intervention: 0 g fiber from SCF/d
Number of subjects: 14
Study 24586534 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vaginal gel and oral tablet regimens (PrEP)
Number of subjects: 102
Study 23096142 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation therapy with drifting sinus gratings (n=8), performed 5 times a week over 4 weeks, 2×20 min sessions, combined with computer games
Number of subjects: 15
Study 23096142 — intervention group
Group type: COMPARATOR
Intervention: Control group with only computer games with a neutral background (n=7)
Number of subjects: 15
Study 20103069 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic skill training protocol with proficiency targets
Number of subjects: 14
Study 20103069 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic skill training protocol without proficiency targets
Number of subjects: 14
Study 18575077 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/day
Number of subjects: 25620
Study 18575077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 25620
Study 18575077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of telmisartan and ramipril
Number of subjects: 25620
Study 18575077 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25620
Study 15953937 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 54
Study 15953937 — intervention group
Group type: COMPARATOR
Intervention: Sit-up exercise
Number of subjects: 54
Study 11832851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free mesh repair (n=175)
Number of subjects: 299
Study 11832851 — intervention group
Group type: COMPARATOR
Intervention: Non-mesh modified Bassini's repair (n=164)
Number of subjects: 299
Study 10398312 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate (50 to 75 mg of elemental zinc orally daily) for 3 years after 1 year observation in Gr A.
Number of subjects: 32
Study 10398312 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year followed by zinc supplementation (50 to 75 mg of elemental zinc orally daily) for 2 years in Gr B.
Number of subjects: 32
Study 10398312 — intervention group
Group type: COMPARATOR
Intervention: No intervention in Gr C (zinc sufficient).
Number of subjects: 32
Study 8523654 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (0.02‐0.05 micrograms.kg‐1.min‐1 administered intravenously throughout the operation)
Number of subjects: 16
Study 8523654 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGE1 administration)
Number of subjects: 16
Study 8523654 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 16
Study 1453605 — intervention group
Group type: COMPARATOR
Intervention: Low hydration (LowH)
Number of subjects: 10
Study 1453605 — intervention group
Group type: EXPERIMENTAL
Intervention: High hydration (HighH)
Number of subjects: 10
Study 2578610 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic peritoneal lavage (2 liters per hour for three days)
Number of subjects: 91
Study 2578610 — intervention group
Group type: COMPARATOR
Intervention: Control group (full supportive treatment only)
Number of subjects: 91
Study 2578610 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic peritoneal lavage
Number of subjects: 91
Study 30739747 — intervention group
Group type: EXPERIMENTAL
Intervention: MISTIE treatment (1·0 mg alteplase every 8 h for up to nine doses)
Number of subjects: 506
Study 30739747 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 506
Study 30739747 — intervention group
Group type: EXPERIMENTAL
Intervention: MISTIE treatment
Number of subjects: 506
Study 30103205 — intervention group
Group type: EXPERIMENTAL
Intervention: In Favour of Myself (after-school setting)
Number of subjects: 224
Study 30103205 — intervention group
Group type: COMPARATOR
Intervention: In Favour of Myself (school-based setting)
Number of subjects: 224
Study 26085198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligence seven needle therapy
Number of subjects: 64
Study 24988965 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (melaxen)
Number of subjects: 60
Study 24988965 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study 24190686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (counseling sessions, distribution of tailored educational brochures, demonstration of home air pollution, and 2 follow-up counseling telephone calls)
Number of subjects: 250
Study 24190686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 250
Study 24190686 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (distribution of standard leaflets)
Number of subjects: 250
Study 21414953 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg t.i.d.
Number of subjects: 42
Study 21414953 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 20 mg t.i.d.
Number of subjects: 42
Study 21414953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19051221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ile/Ile genotype of GST-P1
Number of subjects: 209
Study 19051221 — intervention group
Group type: COMPARATOR
Intervention: Ile/Val + Val/Val genotypes
Number of subjects: 209
Study 17580458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic A (Initial, GC)
Number of subjects: 6
Study 17580458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic B (Triceram, Esprident)
Number of subjects: 6
Study 17580458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic C (Cercon Ceram S, DeguDent)
Number of subjects: 6
Study 14709454 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron intravenously (high-risk group)
Number of subjects: 162
Study 14709454 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (low-risk group)
Number of subjects: 162
Study 14709454 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall institutional PONV incidence
Number of subjects: 162
Study 14709454 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with ondansetron (both groups)
Number of subjects: 162
Study 11211889 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b + ribavirin (IFN + RIBA)
Number of subjects: 118
Study 11211889 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha-2b + amantadine (IFN + AMANT)
Number of subjects: 118
Study 9737826 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0